Viralytics secures key EU patent

Sydney, Australia-based Viralytics says it has been granted a European patent covering its core technology. The company had announced in May that a Notice of Allowance had been received and that, subject to the completion of a number of administrative matters, a patent was expected to be granted later in the year. The patent provides Viralytics with exclusive use of Coxsackie A group viruses (including the firm's lead product Cavatak) for the treatment of all cancers expressing the ICAM-1 molecule until 2020.